Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in colorectal cancer patients

ABSTRACT: Interventions: Drug : Experimental group takes olanzapine 5mg po a day for 3days. Control group takes placebo 5mg po a day for 3days. Primary outcome(s): Check the patient experience nausea or vomitting Primary Purpose : Treatment, Intervention Model : Parallel, Blinding/Masking : Double, Blinding Target : Subject, Investigator, Allocation : RCT

DISEASE(S): Diseases Of The Digestive System

PROVIDER: 2511337 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Area postrema cell types that mediate nausea-associated behaviors

Project description:Nausea, the unpleasant sensation of visceral malaise, remains a mysterious process. The area postrema is implicated in some nausea responses, and contains poorly understood brain-resident sensory neurons that are anatomically privileged to detect bloodborne signals. To investigate nausea mechanisms, we built an area postrema cell atlas through single-nucleus RNA sequencing, revealing a few neuron types. Using mouse genetic tools for cell-specific manipulation, we discovered excitatory neurons that induce nausea-related behaviors, with one neuron type mediating aversion imposed by multiple poisons. Nausea-associated responses were observed to agonists of identified area postrema receptors, and suppressed by targeted cell ablation and/or gene knockout. Anatomical mapping revealed a distributed network of long-range excitatory but not inhibitory projections with subtype-specific patterning. These studies reveal the basic organization of area postrema nausea circuitry, and provide a framework towards understanding and therapeutically controlling nausea.

2020-12-07 | GSE160938 | GEO

Effect of gabapentin capsules on nausea and vomiting

Project description:Intervention 1: In the intervention group: gabapentin capsule of 300 milligrams three times a day from one day Chemotherapy will be used until the end of the chemotherapy period. Intervention 2: In the control group, for the reduction of nausea and vomiting after chemotherapy, a routine of three drugs (dexamethasone, ranitidine and ketril) will be used.;Treatment - Drugs;Treatment - Drugs;In the intervention group: gabapentin capsule of 300 milligrams three times a day from one day Chemotherapy will be used until the end of the chemotherapy period.;In the control group, for the reduction of nausea and vomiting after chemotherapy, a routine of three drugs (dexamethasone, ranitidine and ketril) will be used Primary outcome(s): Nausea and vomiting. Timepoint: after intervention. Method of measurement: By grade. Study Design: Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.

| 2493651 | ecrin-mdr-crc

Molecular classification of the placebo effect in nausea by mass spectrometry

Project description:In this proof-of-concept study, we tested whether placebo effects can be monitored and predicted by plasma proteins. In a randomized controlled design, 90 participants were exposed to a nauseating stimulus on two separate days and were randomly allocated to placebo treatment or no treatment on the second day. Significant placebo effects on nausea, motion sickness, and gastric activity could be verified. Using state-of-the-art proteomics, 74 differentially regulated proteins were identified as correlates of the placebo effect. Gene ontology (GO) enrichment analyses identified acute-phase proteins and microinflammatory proteins to be involved, and the identified GO signatures predicted day-adjusted scores of nausea indices in the placebo group. We also performed GO enrichment analyses of specific plasma proteins predictable by the experimental factors or their interactions and identified ‘grooming behavior’ as a prominent hit. Finally, Receiver Operator Characteristics allowed to identify plasma proteins differentiating placebo responders from non-responders, comprising immunoglobulins and proteins involved in oxidation reduction processes and complement activation. Plasma proteomics are a promising tool to identify molecular correlates and predictors of the placebo effect in humans.

2020-11-13 | PXD020563 | Pride

Nausea in specific phobia of vomiting.

Project description: Not available

| S-EPMC4217587 | biostudies-literature

Activation of GFRAL+ Neurons Induces Hypothermia and Glucoregulatory Responses Associated with Nausea and Torpor

Project description:GFRAL-expressing neurons actuate aversion and nausea, are targets for obesity treatment and may mediate metformin effects by long-term GDF15-GFRAL agonism. If GFRAL+ neurons acutely regulate glucose and energy homeostasis is however underexplored. Here, we report that cell-specific activation of GFRAL+ neurons using a variety of techniques causes a torpor-like state, including hypothermia, the release of stress hormones, a shift from glucose to lipid oxidation, and impaired insulin sensitivity, glucose tolerance and skeletal muscle glucose uptake but augmented glucose uptake in visceral fat. Metabolomic analysis of blood and transcriptomics of muscle and fat indicate alterations in ketogenesis, insulin signaling, adipose tissue differentiation and mitogenesis, or energy fluxes. Our findings reveal that acute GFRAL+ neuron activation induces endocrine and gluco- and thermoregulatory responses associated with nausea and torpor. While chronic activation of GFRAL signaling promotes weight loss in obesity, these results show that acute activation of GFRAL+ neurons causes hypothermia and hyperglycemia.

2024-03-21 | GSE255540 | GEO